These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase
Abbott Laboratories		Zemplar Injection	Paricalcitol	2001022	Hyperparathyroidism, Secondary	Phase IV

Clinical Study Summary

Protocol No. 2001022: A Phase 4, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Safety and Effectiveness of Zemplar® (Paricalcitol Injection) in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric End Stage Renal Disease Subjects on Hemodialysis

Greenbaum LA, Benador N, Goldstein SL, et al. Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis. American Journal of Kidney Diseases 2007; 49(6):814-823.

Company Study

No document provided.